# Psilocybin Type: Technology Source: GetYourBrief — https://getyourbrief.com/entity/psilocybin-technology Canonical HTML page: https://getyourbrief.com/entity/psilocybin-technology ## Timeline - **2026-03-15**: Valuation Period — Expected timeframe for determining the fair market value of the equity investment. - **2026-03**: Palliative Care Findings — New research confirms high efficacy rates for mitigating end-of-life distress in oncology settings. - **2026-02-20**: Option Exercised — PsyLabs officially triggers the put option, requiring an equity investment from PBM. - **2026-02-20**: Put Option Exercised — PsyLabs Ltd. formally exercises its rights under the Put Option Agreement with Psyence BioMed. - **2026-02-20**: Strategic Investment Announced — Psyence BioMed announces it will make an equity investment in PsyLabs at fair market value. - **2025-01-01**: Put Option Established — Psyence BioMed and PsyLabs enter into a strategic put option agreement. - **2024**: Phase 3 Trials — Large-scale multi-site trials aim to provide definitive data for regulatory approval. - **2022-01**: SAP Expansion — Canada formally expands the Special Access Program to include restricted psychedelic substances. - **2022**: SAP Expansion — Canada amends the Special Access Program to include restricted psychedelic substances. - **2020-08**: Canadian Exemptions — Health Canada grants the first legal exemptions for psilocybin use to four terminally ill patients. - **2020**: Regulatory Shift — Health Canada begins granting Section 56 exemptions for terminally ill patients. - **2018-10**: FDA Breakthrough Status — FDA grants Breakthrough Therapy designation to psilocybin for treatment-resistant depression. - **2016**: Foundational Research — Johns Hopkins and NYU publish landmark studies on psilocybin for cancer-related distress. ## Recent coverage (7 stories, network-wide) ### Psychedelics Outperform Nicotine Patches in Landmark Smoking Cessation Study 2026-03-17 16:00:29 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2 A new comparative study reveals that psychedelic-assisted therapy significantly exceeds the efficacy of standard nicotine patches for long-term smoking cessation. The findings suggest a paradigm shift in treating nicotine addiction, moving from continuous replacement to episodic, transformative intervention. Full story: https://getbiobrief.com/story/psychedelics-vs-nicotine-patches-smoking-cessation ### Psilocybin Therapy Shows Unprecedented Efficacy in Smoking Cessation Trials 2026-03-10 16:53:46 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 3 A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy. Full story: https://getbiobrief.com/story/psilocybin-smoking-cessation-clinical-trial-results ### Psilocybin Shows Clinical Promise in Easing End-of-Life Existential Distress 2026-03-06 15:49:59 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2 Emerging clinical research indicates that psilocybin-assisted therapy can significantly alleviate existential dread and depression in terminally ill patients. This development marks a potential paradigm shift in palliative care, moving beyond physical pain management to address deep-seated psychological trauma. Full story: https://getbiobrief.com/story/psilocybin-end-of-life-clinical-promise ### Psilocybin Research Signals Paradigm Shift in End-of-Life Palliative Care 2026-03-06 15:49:55 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2 Clinical research into psilocybin-assisted therapy is demonstrating significant potential in mitigating existential distress and depression among terminally ill patients. These findings are driving a re-evaluation of palliative care protocols and accelerating the push for expanded regulatory access to psychedelic-based treatments. Full story: https://gethealthbrief.com/story/psilocybin-palliative-care-research-trends ### Psyence BioMed to Invest in PsyLabs Following Put Option Exercise 2026-02-21 00:41:18 · Sector: startups · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Psyence Biomedical Ltd. (Nasdaq: PBM) has announced a strategic equity investment in PsyLabs Ltd. after the manufacturer exercised its rights under a previously established put option agreement. This move strengthens the relationship between the biopharmaceutical developer and its primary supplier of nature-derived psychedelic compounds. Full story: https://getstartupbrief.com/story/psyence-biomed-psylabs-equity-investment-put-option ### Psyence BioMed Secures Supply Chain via Strategic PsyLabs Equity Investment 2026-02-21 00:40:46 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a pre-existing put option agreement. The transaction reinforces the vertical integration between the clinical-stage developer and its primary source of pharmaceutical-grade, nature-derived psychedelic compounds. Full story: https://getbiobrief.com/story/psyence-biomed-psylabs-equity-investment-put-option ### Psyence BioMed Strengthens Supply Chain with Strategic PsyLabs Investment 2026-02-21 00:39:13 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a previously established put option. This move deepens the integration between the biopharmaceutical developer and its primary manufacturer of pharmaceutical-grade psychedelic compounds. Full story: https://gethealthbrief.com/story/psyence-biomed-psylabs-equity-investment-put-option --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.